Ειδήσεις: PHASE II | PXAI

Version	Description	Date
8.42	[ADDED SOURCE REGISTRY LIST VIEW]	04/03/2026 16:19
8.41	[LOCALIZED INDEX.PHP MENU AND MODALS TO US ENGLISH]	04/03/2026 16:11
8.40	[TRANSLATED FRONTEND TO US ENGLISH]	04/03/2026 16:10
8.41	[RESTORED DETAILED SOURCES VIEW (ARTICLES + EVENTS) IN US ENGLISH]	04/03/2026 15:50
8.41	[RESTORED DETAILED SOURCES VIEW (ARTICLES + EVENTS) IN US ENGLISH]	04/03/2026 15:46
8.40	[REVERTED TO STANDARD TABLE LAYOUT (US ENGLISH)]	04/03/2026 15:40
8.39	[FIXED DB CONNECTION SCOPE IN SOURCES LOGIC]	04/03/2026 15:38
8.38	[TRANSLATED SOURCES VIEW TO US ENGLISH]	04/03/2026 15:01
8.37	[FULL FRONTEND TRANSLATION (MENU, FEED, COMMENTS, TTS) TO US ENGLISH.]	04/03/2026 14:58
8.67	[MANUAL OVERRIDE OF GREEK MENU ITEMS]	04/03/2026 13:36
8.66	[NGINX OPTIMIZED MENU FIX]	04/03/2026 13:33
8.65	[FIXED GREEK MENU ITEMS]	04/03/2026 13:32
8.60	[MENU & UI LOCALIZATION TO US ENGLISH]	04/03/2026 13:30
8.50	[FULL TRANSLATION TO US ENGLISH]	04/03/2026 13:27
9.75	[INJECTED EVENT FUSION_SUMMARY INTO FEED LOOPS TO DISPLAY AI TAGS CORRECTLY]	26/02/2026 14:44

24/03 18:19 defenseworld.net

VistaGen Therapeutics Highlights Fasedienol PALISADE-4 Readout Timing, AI Tools to Tackle Placebo Effect

VistaGen fasedienol PALISADE Phase III social anxiety Fast Track

19/03 07:02 defenseworld.net

Monte Rosa Therapeutics touts molecular glue pipeline, tees up GFORCE updates and Phase II plans

Monte Rosa Therapeutics molecular glue degrader pipeline GFORCE Phase II inflammation

18/03 07:06 defenseworld.net

4D Molecular Therapeutics Highlights 4D-150 Phase III Momentum, DME Plans, Cash Runway at Leerink Conference

4D Molecular Therapeutics 4D‑150 Phase III wet AMD DME gene therapy

17/03 09:06 defenseworld.net

Edgewise Therapeutics Talks Phase III Becker Readout, EDG-7500 HCM Data Due in Q2 at Conference

Edgewise Therapeutics Becker muscular dystrophy Phase III cardiovascular ejection fraction NT‑proBNP

16/03 09:02 defenseworld.net

Cadrenal Therapeutics Highlights CAD-1005 In-License, Maps Phase III Path for HIT at Investor Forum

Cadrenal Therapeutics CAD‑1005 HIT Phase III heparin‑induced thrombocytopenia in‑licensing

16/03 09:02 defenseworld.net

Cadrenal Therapeutics Highlights CAD-1005 In-License, Maps Phase III Path for HIT at Investor Forum

Cadrenal Therapeutics CAD‑1005 HIT Phase III heparin‑induced thrombocytopenia in‑licensing

Loading...